Physician profile
James E Stanislaw
NPI 1457307274
$911.76
in general payments reported to CMS, 2019-2025
16 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.45 · 2020: $103 · 2021: $195 · 2022: $143 · 2023: $100 · 2024: $45.90 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $156.67 | 2020-2025 | Evos, Trigen, Maverick |
| Axogen | $146.32 | 2025 | |
| Zimmer Biomet Holdings, INC. | $140.39 | 2020-2022 | |
| Pacira Therapeutics, INC. | $137.58 | 2019-2021 | |
| Bioventus LLC | $40.09 | 2023 | Exogen Ultrasound Bone Healing System |
| Abbott Laboratories | $37.94 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $35.65 | 2025 | |
| Piedmont Plus Innovation | $32.33 | 2025 | |
| Baxter Healthcare | $29.08 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $28.87 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $26.83 | 2021-2023 | Xiaflex |
| Heron Therapeutics, INC. | $24.07 | 2023 | Zynrelef |
| Stryker Corporation | $22.67 | 2021 | |
| Medartis INC. | $20.49 | 2021 | |
| Kci USA, INC. | $19.10 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baudax Bio INC. | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stanislaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.